Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD known ✓ | O00329 | 2/20 | 0.45 |
| ▸ | PIK3CA known ✓ | P42336 | 2/20 | 0.45 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | AGXT | P21549 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.46 |
| ▸ | PRKDC | P78527 | 3/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.44 |
| ▸ | PLOD3 | O60568 | 2/20 | 0.44 |
| ▸ | PLOD1 | Q02809 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL875323 | 0.98 | KMO (0.55) | KMOLMNAAGXTAKR1C3PRKDC | |
| SCHEMBL28377969 | 0.90 | KMO (0.48) | KMOLMNAAGXTAKR1C3PRKDC | |
| Hydrochloric Acid SCHEMBL2379090 | 0.84 | KDM4E (0.50) | AGXTALDH1A1MAPTMEN1NPC1 | |
| Hydrochloric Acid SCHEMBL29957597 | 0.84 | KDM4E (0.50) | AGXTALDH1A1MAPTMEN1NPC1 | |
| SCHEMBL12266120 | 0.84 | MGLL (0.50) | KMOLMNAALDH1A1MAPTMEN1 | |
| Hydrochloric Acid SCHEMBL29955844 | 0.83 | ALDH1A1 (0.49) | LMNAAGXTALDH1A1MAPTMEN1 | |
| SCHEMBL19492816 | 0.82 | ENPP2 (0.48) | AGXTALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL488570 | 0.82 | KDM4E (0.51) | AGXTALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL1529259 | 0.81 | ALDH1A1 (0.50) | LMNAAGXTALDH1A1MAPTMEN1 | |
| SCHEMBL27329825 | 0.80 | LMNA (0.71) | KMOLMNAAGXTAKR1C3PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-2970193-B1 | PYRROLE AMIDE INHIBITORS | ABBVIE INC (US) | 2018-07-25 | — | — | EP | disclosed |
| US-9932340-B2 | Substituted indoles | ABBVIE INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170349589-A9 | Substituted Indoles | ABBVIE INC. (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170174688-A1 | Substituted Indoles | ABBVIE INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-9493411-B2 | Pyrrole-3-carboxamide bromodomain inhibitors | ABBVIE INC. (US) | 2016-11-15 | — | — | US | disclosed |
| EP-2970193-A1 | PYRROLE AMIDE INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014165127-A1 | PYRROLE AMIDE INHIBITORS | ABBVIE INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140275079-A1 | PYRROLE AMIDE INHIBITORS | ABBVIE INC. | 2014-09-18 | — | — | US | disclosed |
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | TRANSTECH PHARMA, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| EP-1730118-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | Transtech Pharma, Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005080346-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | PTPRO, PTPN5, PTPRE | PIK3CD 407/4885PIK3CA 265/4885HDAC3 2756/4885 |
| US-20170174688-A1 | Substituted Indoles | SUV39H2, SUV39H1, IDO1 | PIK3CD 1928/4885PIK3CA 1837/4885HDAC3 245/4885 |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | PTPRO, PTPN5, PTPRE | PIK3CD 407/4885PIK3CA 265/4885HDAC3 2756/4885 |
| US-20140275079-A1 | PYRROLE AMIDE INHIBITORS | HDAC10, ARG1, CDK20 | PIK3CD 2094/4885PIK3CA 1303/4885HDAC3 1013/4885 |
| US-20170349589-A9 | Substituted Indoles | SUV39H2, SUV39H1, IDO1 | PIK3CD 1928/4885PIK3CA 1837/4885HDAC3 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.